Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 5/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354708 | 1.00 | HTT (0.62) | HTTLMNAHSD17B10HPGDL3MBTL1 | |
| SCHEMBL6932025 | 1.00 | HTT (0.62) | HTTLMNAHSD17B10HPGDL3MBTL1 | |
| SCHEMBL22043642 | 0.89 | L3MBTL1 (0.53) | HTTLMNAHPGDL3MBTL1CYP19A1 | |
| SCHEMBL31552701 | 0.89 | L3MBTL1 (0.53) | HTTLMNAHPGDL3MBTL1CYP19A1 | |
| SCHEMBL25295761 | 0.85 | HTT (0.49) | HTTLMNAHSD17B10HPGDL3MBTL1 | |
| SCHEMBL18762883 | 0.85 | HTT (0.49) | HTTLMNAHSD17B10HPGDL3MBTL1 | |
| SCHEMBL23678473 | 0.81 | CYP11B2 (0.41) | HTTCYP19A1CYP11B1CYP11B2SRD5A1 | |
| SCHEMBL17988347 | 0.78 | HTT (0.70) | HTTLMNAHSD17B10HPGDL3MBTL1 | |
| SCHEMBL12609506 | 0.77 | HTT (0.62) | HTTLMNAHSD17B10HPGDL3MBTL1 | |
| SCHEMBL4344367 | 0.77 | HTT (0.62) | HTTLMNAHSD17B10HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669070-A | Synthesis method of O- (dialkyl phosphinic group) ketoxime | 成都理工大学 | 2020-01-10 | — | — | CN | claimed |
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4208448-B1 | ACRYLAMIDE DERIVATIVES | NRG THERAPEUTICS LTD (GB) | 2025-04-23 | — | — | EP | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
| EP-0915087-B1 | Sulfonamide substituted fused five-membered ring compounds, their use as medicaments as well as pharmaceutical compositions containing them | AVENTIS PHARMA GMBH (DE) | 2003-04-02 | — | — | EP | disclosed |
| US-6015822-A | ANTIULCER, ANTIDIARRHEA, AND ANTIARRHYTHMIA AGENTS; CARDIOVASCULAR AND GASTROINTESTINAL DISORDERS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-01-18 | — | — | US | disclosed |
| EP-0915087-A2 | Sulfonamide substituted fused five-membered ring compounds, their use as medicaments as well as pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-05-12 | — | — | EP | disclosed |
| EP-0538134-B1 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMA (IL) | 1997-03-12 | — | — | EP | disclosed |
| US-5486541-A | FOR TREATING PARKINSON*S DISEASE, MEMORY DISORDERS, ALZHEIMER*S DISEASE, DEPRESSION OR HYPERACTIVE SYNDROME | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-01-23 | — | — | US | disclosed |
| EP-0538134-A2 | Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | HTT 685/4885LMNA 1708/4885HSD17B10 169/4885 |
| US-20230312466-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | HTT 3804/4885LMNA 3307/4885HSD17B10 653/4885 |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | HTT 22/4885LMNA 478/4885HSD17B10 1615/4885 |
| US-20240067614-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, CXCR2 | HTT 3726/4885LMNA 3273/4885HSD17B10 633/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | HTT 119/4885LMNA 1086/4885HSD17B10 1544/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | HTT 174/4885LMNA 1162/4885HSD17B10 1179/4885 |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | HTT 16/4885LMNA 50/4885HSD17B10 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.